Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

Lung cancer, the second-most common cancer in the U.S., is often associated with smoking — but even those who have never had ...

While there is no definitive evidence linking chemicals to increased cancer risk in young people, this is an area of intense ...

UC San Diego study of global lung cancer shows mutations that lead to cancer are common in people who live in cities with bad air pollution. But cancer mutations are quite close to normal among ...

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...

Recent developments in protein-protein interactions (PPI) give hope for patients with advanced or untreatable diseases.

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor ...

Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy (sunvozertinib) to become the only ...

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%.

A new study published in Nature says air pollution may be driving lung cancer development in people who have little to no ...